In a 78-week study examining the interchangeability of infliximab with the biosimilar SB2, the treatments demonstrated long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis. Across all the study’s treatment groups, patients had similar treatment response rates, and the long-term clinical profile of SB2 was comparable with infliximab…
![](https://www.the-rheumatologist.org/wp-content/uploads/2017/05/GenericDrugs_500x270_v2-e1682634564415-150x150.jpg)